Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

AZN

Astrazeneca plc ADR

Nov 07 • 04:00PM ET

84.58

+0.81 0.97 %

Healthcare • Drug Manufacturers - General • United Kingdom • NASD

Peers: ABBV PFE JNJ MRK NVS BMY GSK SNY LLY AMGN

| Held by: QQQ QQQM PVAL CGGO DIHP DFIC PPH AVDE FVD TQQQ

Scroll to Statements

Index	NDX	P/E	28.05	EPS (ttm)	3.01	Insider Own	0.02%	Shs Outstand	3.10B	Perf Week	2.65%
Market Cap	262.24B	Forward P/E	16.34	EPS next Y	5.18	Insider Trans	0.00%	Shs Float	3.10B	Perf Month	-0.54%
Enterprise Value	286.77B	PEG	2.31	EPS next Q	1.06	Inst Own	16.22%	Short Float	0.23%	Perf Quarter	14.19%
Income	9.41B	P/S	4.51	EPS this Y	11.68%	Inst Trans	-4.40%	Short Ratio	1.52	Perf Half Y	25.17%
Sales	58.12B	P/B	5.71	EPS next Y	12.88%	ROA	8.58%	Short Interest	7.00M	Perf YTD	29.09%
Book/sh	14.80	P/C	32.05	EPS next 5Y	12.13%	ROE	21.73%	52W High	86.57 -2.30%	Perf Year	27.63%
Cash/sh	2.64	P/FCF	20.22	EPS past 3/5Y	285.92% 34.53%	ROIC	13.08%	52W Low	61.24 38.11%	Perf 3Y	41.68%
Dividend Est.	1.62 (1.92%)	EV/EBITDA	14.88	Sales past 3/5Y	12.66% 17.18%	Gross Margin	73.25%	Volatility	1.62% 1.55%	Perf 5Y	67.09%
Dividend TTM	1.56 (1.85%)	EV/Sales	4.93	EPS Y/Y TTM	44.63%	Oper. Margin	21.89%	ATR (14)	1.57	Perf 10Y	165.22%
Dividend Ex-Date	Aug 08, 2025	Quick Ratio	0.69	Sales Y/Y TTM	13.27%	Profit Margin	16.19%	RSI (14)	59.79	Recom	1.55
Dividend Gr. 3/5Y	2.54% 2.10%	Current Ratio	0.88	EPS Q/Q	76.32%	SMA20	1.47%	Beta	0.33	Target Price	95.43
Payout	66.95%	Debt/Eq	0.71	Sales Q/Q	11.31%	SMA50	3.90%	Rel Volume	0.89	Prev Close	83.77
Employees	94300	LT Debt/Eq	0.57	Earnings	Nov 06 BMO	SMA200	13.22%	Avg Volume	4.61M	Price	84.58
IPO	May 12, 1993	Option/Short	Yes / Yes	EPS/Sales Surpr.	0.00% 0.00%	Trades		Volume	4,105,756	Change	0.97%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-27-25	Resumed	Jefferies	Buy
Oct-16-25	Downgrade	Deutsche Bank	Hold → Sell
Apr-15-25	Initiated	Exane BNP Paribas	Outperform	$75
Feb-13-25	Upgrade	UBS	Neutral → Buy
Feb-12-25	Initiated	Morgan Stanley	Overweight
Nov-20-24	Upgrade	UBS	Sell → Neutral
Nov-06-24	Upgrade	Deutsche Bank	Sell → Hold
Sep-13-24	Downgrade	Deutsche Bank	Hold → Sell
May-30-24	Initiated	Goldman	Buy	$97
Apr-16-24	Upgrade	Deutsche Bank	Sell → Hold
Feb-08-24	Downgrade	Deutsche Bank	Hold → Sell
Jan-23-24	Initiated	Morgan Stanley	Overweight	$85
Jan-16-24	Resumed	UBS	Sell
Jan-03-24	Downgrade	Jefferies	Buy → Hold	$78.50 → $70
Dec-18-23	Initiated	HSBC Securities	Buy	$78
Sep-25-23	Upgrade	Jefferies	Hold → Buy	$66.50 → $80
Jul-14-23	Initiated	HSBC Securities	Buy
Jul-12-23	Upgrade	UBS	Neutral → Buy
Jul-05-23	Downgrade	Deutsche Bank	Buy → Hold
Apr-11-23	Upgrade	Morgan Stanley	Equal-Weight → Overweight

Show Previous Ratings

Today 11:28AM	Pfizer Discusses Drug Pricing Deal, Metsera Buyout Dispute on Q3 Call (Zacks)
09:38AM	Analyst Report: AstraZeneca PLC (Morningstar Research)
06:30AM	CEO Says AstraZeneca Can Absorb Costs of Trump-Driven US Deals (The Daily Upside)
03:32AM	Company News for Nov 7, 2025 (Zacks)
Nov-06-25 04:42PM	Why AstraZeneca Stock Topped the Market on Thursday (Motley Fool)
04:08PM	Loading…
04:08PM	AstraZeneca Bounds Into A Chase Zone As Cancer Drugs Drive Sales Beat (Investor's Business Daily)
02:37PM	Novo Nordisk and Eli Lilly Can Sell Their Weight-Loss Drugs to Medicare Market (Barrons.com)
02:05PM	AstraZeneca PLC (AZN) Q3 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic Advances (GuruFocus.com)
01:42PM	Stocks in Focus Globally: Nissan, ArcelorMittal, AstraZeneca (The Wall Street Journal)
11:45AM	AZN Q3 Earnings Top Estimates, Sales Rise As Most Key Drugs Outperform (Zacks)
11:41AM	AstraZeneca Stuns Wall Street With Surprise Profit Surge (GuruFocus.com)
11:14AM	Earnings Data Deluge (Zacks)
10:36AM	Pre-Markets Improve on Big Earnings Morning (Zacks)
09:30AM	Compared to Estimates, Astrazeneca (AZN) Q3 Earnings: A Look at Key Metrics (Zacks)
08:45AM	Stocks Around the World in Focus: Nissan, ArcelorMittal, Deutsche Boerse (The Wall Street Journal)
08:34AM	Loading…
08:34AM	AstraZeneca Shares Jump; Drugmaker Keeps Outlook As Cancer Drug Sales Soar (Investor's Business Daily)
07:51AM	AstraZeneca CEO bullish on record revenue numbers and US growth (Yahoo Finance Video)
02:59AM	AstraZeneca beats forecasts in Q3, reaffirms full-year guidance (Investing.com)
02:39AM	AstraZeneca Revenue Climbs on Pipeline Strength (The Wall Street Journal)
Nov-05-25 07:00PM	Tesla shareholder vote, Fed talk, mortgage rates: What to Watch (Yahoo Finance Video)
01:54PM	Eli Lilly Stock Sees RS Rating Rise To 77 (Investor's Business Daily)
11:37AM	Amgen's Q3 Earnings & Sales Beat, 2025 Outlook Raised, Stock Up (Zacks)
Nov-04-25 11:15AM	Pfizer Q3 Earnings Beat Estimates, Sales Decline as COVID Demand Cools (Zacks)
Oct-31-25 07:00PM	SNAP benefits expire, open enrollment, earnings: What to Watch (Yahoo Finance Video)
02:00PM	Should You Buy, Hold, or Sell BDTX Stock Ahead of Q3 Earnings? (Zacks)
11:07AM	Pfizer Q3 Earnings Loom: Buy, Sell or Hold PFE Stock Ahead of Results? (Zacks)
Oct-30-25 01:14PM	Ionis Beats Q3 Earnings & Sales Estimates, Raises 2025 Outlook (Zacks)
12:41PM	MRK Beats Q3 Earnings Estimates, Narrows 2025 Sales View, Stock Down (Zacks)
09:22AM	Eli Lilly Stock Rises on Earnings as Investors Await Trump Drug Pricing Deal (Barrons.com)
Oct-29-25 04:45PM	Eli Lilly Reports Earnings Thursday as Investors Await Trump Drug Pricing Deal (Barrons.com)
06:15PM	Loading…
Oct-28-25 06:15PM	Astrazeneca (AZN) Stock Declines While Market Improves: Some Information for Investors (Zacks)
12:37PM	Buy, Sell or Hold MRK Stock Ahead of Q3 Earnings? Things to Know (Zacks)
Oct-24-25 04:12PM	Sanofi Jumps As Dupixent Nears $5 Billion In Sales; Trump Drug Talks Continue (Investor's Business Daily)
12:07PM	A GSK Cancer Drug Is Making a Comeback. Its So-So News for the Stock. (Barrons.com)
10:01AM	Sanofi Q3 Earnings Beat, Dupixent Drives Growth as Vaccines Decline (Zacks)
09:29AM	Here's How Eli Lilly's Oncology Drugs Are Poised Ahead of Q3 Earnings (Zacks)
Oct-23-25 11:13AM	3 Pharmaceutical Growth Stocks to Buy and Hold for 10 Years (MarketBeat)
10:39AM	Lilly Up 10% in a Month: Should You Buy, Sell or Hold the Stock? (Zacks)
05:24AM	Roche Raises Full-Year Earnings Outlook as U.S. Drug-Pricing Talks Continue (The Wall Street Journal)
Oct-22-25 10:35PM	J.P. Morgan Maintains a Buy Rating on AstraZeneca PLC (AZN), Sets a £140 PT (Insider Monkey)
02:31PM	AstraZeneca PLC (AZN): A Bull Case Theory (Insider Monkey)
10:29AM	AbbVie Up More Than 30% in 6 Months: How to Play the Stock (Zacks)
Oct-21-25 10:39AM	Did IonQ Just Unlock Quantum Computings True Potential And a Massive Stock Rally? (24/7 Wall St.)
06:51AM	The Zacks Analyst Blog Highlights AstraZeneca, RTX, Applied Materials, Park Aerospace and NetSol Technologies (Zacks)
Oct-20-25 04:28PM	Top Research Reports for AstraZeneca, RTX & Applied Materials (Zacks)
03:45PM	AstraZeneca's Cancer Breakthrough: Enhertu Data Sparks New Hope for Early Breast Cancer Cure (GuruFocus.com)
10:10AM	Here's What to Expect From AbbVie's Oncology Segment in Q3 Earnings (Zacks)
09:50AM	Here's Why Astrazeneca (AZN) is a Strong Momentum Stock (Zacks)
06:53AM	AstraZeneca hails major breakthroughs with breast-cancer drugs (MarketWatch)
Oct-19-25 07:00AM	DATROWAY (datopotamab deruxtecan-dlnk) demonstrated unprecedented median overall survival improvement of five months vs. chemo as 1st-line treatment for patients with metastatic triple-negative breast cancer for whom immunotherapy was not an option (Business Wire)
Oct-18-25 10:35AM	ENHERTU (fam-trastuzumab deruxtecan-nxki) reduced the risk of disease recurrence or death by 53% vs. T-DM1 in patients with high-risk HER2-positive early breast cancer following neoadjuvant therapy in DESTINY-Breast05 Phase III trial (Business Wire)
10:30AM	AstraZeneca, In A Buy Zone, Makes A Big Breast Cancer Splash (Investor's Business Daily)
10:30AM	ENHERTU Reduced the Risk of Disease Recurrence or Death by 53% Versus T-DM1 in Patients with High-Risk HER2 Positive Early Breast Cancer Following Neoadjuvant Therapy in DESTINY-Breast05 Phase 3 Trial (Business Wire)
10:30AM	ENHERTU (fam-trastuzumab deruxtecan-nxki) followed by THP before surgery resulted in a pathologic complete response in 67% of patients with high-risk HER2-positive early-stage breast cancer in DESTINY-Breast11 Phase III trial (Business Wire)
Oct-17-25 06:15PM	Astrazeneca (AZN) Outpaces Stock Market Gains: What You Should Know (Zacks)
04:17PM	TEZSPIRE approved in the US for chronic rhinosinusitis with nasal polyps (Business Wire)
12:20PM	Will Declining Gardasil Sales Ail MRK's Top Line in Q3 Earnings? (Zacks)
12:11PM	Should You Buy, Sell or Hold J&J Stock After Robust Q3 Earnings? (Zacks)
08:10AM	IMFINZI (durvalumab) regimen reduced the risk of disease recurrence or death by 32% in high-risk non-muscle-invasive bladder cancer in the POTOMAC Phase III trial (Business Wire)
08:00AM	IMFINZI (durvalumab)-based regimen reduced the risk of death by 22% in early gastric cancer vs. chemotherapy alone in MATTERHORN Phase III trial (Business Wire)
Oct-16-25 01:55PM	LLY's Oral GLP-1 Pill Scores Another Pair of Diabetes Wins (Zacks)
09:48AM	2 Pharmaceutical Growth Stocks to Buy Now and Hold for Decades (Motley Fool)
07:23AM	AstraZeneca cut to Sell by Deutsche Bank on pipeline doubts, patent risk (Investing.com)
Oct-15-25 01:19PM	Trump Locks In AstraZeneca Deal to Slash Medicaid Drug Prices -- Big Pharma Faces New Reality (GuruFocus.com)
10:00AM	AstraZeneca unveils expanded manufacturing facility in Texas (Business Wire)
09:20AM	Can NSCLC Drug Silevertinib Drive Sustainable Growth for BDTX? (Zacks)
Oct-14-25 09:45AM	Astrazeneca (AZN) is a Top-Ranked Growth Stock: Should You Buy? (Zacks)
08:43AM	Johnson & Johnson Earnings Beat Estimates. Why the Stock Is Dropping. (Barrons.com)
06:20AM	Johnson & Johnson Says It Will Spin Off Orthopaedics Business (Barrons.com)
Oct-13-25 03:24PM	Trumps AstraZeneca Deal Echoes Pfizer Pact. Big Pharmas Political Headaches Are Easing. (Barrons.com)
01:40PM	AZN Strikes Drug Pricing Deal With Trump, Gets 3-Year Tariff Reprieve (Zacks)
09:59AM	US-China Trade Tension Escalates: Should You Seek Refuge in UK ETFs? (Zacks)
09:40AM	Why This 1 Value Stock Could Be a Great Addition to Your Portfolio (Zacks)
07:54AM	Stocks to Watch Monday: Fastenal, Tesla, JPMorgan, Warner Bros. (The Wall Street Journal)
07:00AM	AstraZeneca furthers ambition to redefine cancer care with first data from four major pivotal trials at ESMO (Business Wire)
05:33AM	Stocks to Watch Monday: AMD, Nvidia, Warner Bros, Alibaba (The Wall Street Journal)
03:45AM	Company News for Oct 13, 2025 (Zacks)
Oct-12-25 06:50PM	Analyst Report: AstraZeneca PLC (Morningstar Research)
Oct-10-25 08:27PM	AstraZeneca Cuts Discounted Drug Pricing Deal With the White House. The Stock Is Rising. (Barrons.com)
07:11PM	AstraZeneca Strikes Drug-Pricing Deal With Trump Administration (The Wall Street Journal)
06:39PM	Trump reaches deal with AstraZeneca to lower U.S. drug prices (CNBC TV)
06:39PM	Pres. Trump announces deal with AstraZeneca to lower U.S. drug prices (CNBC TV)
04:38PM	AstraZeneca to Ink Drug-Pricing Deal With Trump Administration (The Wall Street Journal)
03:45PM	AstraZeneca to become latest drugmaker to strike deal with Trump. Its stock is down but outperforming the market. (MarketWatch)
11:57AM	Will Keytruda Continue to Aid Merck's Top Line in Q3 Earnings? (Zacks)
Oct-09-25 12:30PM	AstraZeneca plans to increase investment and scope of its Virginia manufacturing facility to $4.5 billion, creating 3,600 new jobs (Business Wire)
09:52AM	BDTX Stock Hits 52 Week High: Is There More Room for Growth? (Zacks)
06:00AM	Turbine Launches Collaboration with AstraZeneca, Leveraging Turbine's Virtual Disease Models to Rationalize ADC Discovery (PR Newswire)
Oct-08-25 11:15AM	AstraZeneca's Baxdrostat Meets Goal in Resistant Hypertension Study (Zacks)
08:50AM	Here's What to Expect From Pfizer's Oncology Drugs in Q3 Earnings (Zacks)
Oct-07-25 09:43AM	Best Stocks To Watch: Two New IPOs, Pharma Titan AstraZeneca And Electrical Grid Play Emcor Trade Near Buy Points (Investor's Business Daily)
08:39AM	Thermo Fisher's New R&D Alliance With AstraZeneca May Lift Its Stock (Zacks)
07:00AM	Baxdrostat met the primary endpoint in Bax24 Phase III trial in patients with resistant hypertension (Business Wire)
Oct-06-25 01:57PM	Eli Lilly Stock Rises 16% in a Week: Here's What You Should Know (Zacks)
10:11AM	AbbVie Stock on the Move: What Sparked the 6% Jump in the Past Week? (Zacks)
08:50AM	AstraZeneca/Daiichi Sankyo Partnered Breast Cancer Drug Shows Survival Benefit Over Chemotherapy (Benzinga)
08:32AM	How J&J's Innovative Medicines Segment is Poised Ahead of Q3 Results (Zacks)
07:00AM	DATROWAY (datopotamab deruxtecan-dlnk) improved OS and PFS in TROPION-Breast02 (Business Wire)
Oct-03-25 06:15PM	Astrazeneca (AZN) Rises Higher Than Market: Key Facts (Zacks)
04:16PM	How BeOne Medicines, An IBD 50 Stock, Is Taking On Big Names In Cancer Treatment (Investor's Business Daily)

AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company's history roots back to the year 1913 when Astra business was formed. AstraZeneca was founded in 1999 through the merger of Astra AB and Zeneca Group PLC. The company is headquartered in Cambridge, the United Kingdom.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

AZN

Astrazeneca plc ADR

Upgrade your FINVIZ experience